论文部分内容阅读
目的观察国产替罗非班在急性冠脉综合征(ACS)非手术治疗中的安全性和有效性。方法将120例ACS患者随机分两组,治疗组(常规治疗组+国产盐酸替罗非班,60例)和对照组(常规治疗组,60例),观察两组病人住院期间发生主要心血管不良事件、出血并发症及血小板减少情况。结果与对照组相比,治疗组主要心血管不良事件发生率显著降低,两组之间出血并发症发生率无显著差异。结论国产盐酸替罗非班在ACS治疗中可减少心血管不良事件,出血事件无明显增加。
Objective To observe the safety and efficacy of domestic tirofiban in non-surgical treatment of acute coronary syndrome (ACS). Methods A total of 120 patients with ACS were randomly divided into two groups: the treatment group (conventional treatment group + domestic tirofiban hydrochloride 60 cases) and the control group (conventional treatment group, 60 cases). The main cardiovascular events Adverse events, bleeding complications and thrombocytopenia. Results Compared with the control group, the incidence of major cardiovascular adverse events in the treatment group was significantly lower, and there was no significant difference in the incidence of bleeding complications between the two groups. Conclusion Domestic tirofiban hydrochloride can reduce cardiovascular adverse events in patients with ACS, no significant increase in bleeding events.